MonoSol deal for nanocell delivery film
The agreement will see the two companies jointly research, develop and commercialise the delivery of nanoparticles on MonoSol’s PharmFilm delivery technology.
By combining the two technologies, which the companies believe are complementary, the collaboration intends to produce drug candidates that are more convenient, demonstrate greater efficacy at low doses and have a faster onset of action.
Mark Schobel, president and CEO of MonoSol Rx, said: “The size and chemical composition of Midatech's biocompatible nanocells are ideally suited for delivery using our PharmFilm technology, and should provide another avenue for us to extend the commercial potential of new and currently marketed drugs.
“Most importantly, the mating of MonoSol Rx's and Midatech's technologies will enable the oral delivery of many challenging drugs that up to now could not be delivered orally."
Midatech’s nanocells are water soluble, can deliver a multiple or multivalent drugs on a single particle and can be administered by various routes.
The companies believe these traits make it well suited for delivery using MonoSol’s PharmFilm, which can carry uniform, accurate doses and be administered buccally, sublingually or intragastrically.
R&D of potential drug candidates will take place at MonoSol Rx's facility in Portage, Indiana and Midatech's sites in Spain and Switzerland. Further details of the collaboration have not been disclosed.
